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Background: The hypermethylation of Alcohol dehydrogenase iron containing 1 (ADHFE1) was recently reported to
be associated with colorectal cancer (CRC) differentiation. However, the effect of alcohol on ADHFE1
hypermethylation in CRC is still unclear.
Methods: The methylation status and expression levels of ADHFE1 were investigated in primary tumor tissues and
adjacent normal tissues of 73 patients with CRC, one normal colon cell line, and 4 CRC cell lines (HT-29, SW480,
DLD-1, and LoVo) by quantitative methylation-specific polymerase chain reaction (QMSP) and real-time reverse
transcription polymerase chain reaction (real time PCR), respectively. The effect of alcohol on the methylation status
of ADHFE1 was analyzed in HT-29, SW480, DLD-1, and CCD18Co cells using QMSP, real-time PCR, immunoblot, and
cell proliferation assay.
Results: ADHFE1 was hypermethylated in 69 of 73 CRC tissues (95%) compared to adjacent normal tissues (p < 0.05).
The mRNA expression of ADHFE1 was significantly reduced in CRC compared to adjacent normal tissues (p < 0.05) and
its expression was decreased in the alcohol consumption group (p < 0.05). ADHFE1 was hypermethylated and its
expression was decreased in 4 CRC cell lines compared with normal colon cell line. Alcohol induced hypermethylation
of ADHFE1, decreased its expression, and stimulated cell proliferation of HT-29, SW480, and DLD-1cells.
Conclusion: These results demonstrate that the promoter hypermethylation of ADHFE1 is frequently present in
CRC and alcohol induces methylation-mediated down expression of ADHFE1 and proliferation of CRC cells.
Keywords: ADHFE1, Colorectal cancer, Hypermethylation, Alcohol, Quantitative methylation-specific polymerase
chain reactionBackground
Aberrant DNA methylation leads to the suppression of
tumor suppressor gene expression as an epigenetic events
[1]. In mammals, DNA methylation occurs only at CpG
dinucleotide pairs, in which a 5′ cytosine residue is sit-
uated adjacent to a guanine residue. Hypermethylation
of CpG-rich or intermediate promoters has been shown to
inactivate downstream gene expression, and promoter
hypermethylation of tumor suppressor genes is frequently* Correspondence: parksh@korea.ac.kr
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unless otherwise stated.observed in many human malignancies, and may contrib-
ute to disease pathogenesis [2-5]. Colorectal cancer (CRC)
is one of the most common cancers in Korea, and its in-
cidence has been steadily increasing. Epigenetic alter-
ations that are commonly found in CRCs include DNA
methylation of tumor suppressor genes [6,7] and histone
deacetylation [8].
Alcohol overconsumption is a well-known risk factor
for the development as well as progression of various
types of cancers, including CRC [9]. When alcohol is
consumed, it is metabolized by alcohol dehydrogenases
(ADH) and cytochrome P450 subenzyme 2E1 (CYP2E1),
which catalyze the oxidation of alcohol to acetaldehyde
[10]. Alcohol dehydrogenases (ADH) are a well-definedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinicopathologic characteristics of colorectal
cancer patients and methylation status of ADHFE1
Characteristics No. of cases Methylation status of ADHFE1
(PMR, %)
Median (range) p-Value
Normal 73 3.25 (±0.50) < 0.001†
Colorectal cancer 73 74.89 (±8.06)
Age (years) 0.957
≤ 65 35 75.35 (±13.73)
> 65 38 74.46 (±9.13)
Gender 0.114
Female 27 91.55 (±16.46)
Male 46 65.10 (±8.21)
Location 0.627
Colon 46 77.91 (±10.45)
Rectum 27 69.73 (±12.77)
TNM Stage 0.252
I,II 32 85.40 (±14.10)
III,IV 41 66.68 (±9.18)
Size (mm) 0.276
≤ 25 44 67.71 (±7.81)
> 25 29 85.78 (±16.48)
Alcohol consumption 0.012†
Non-drinking 36 95.27 (±13.15)
Drinking 37 55.06 (±8.41)
Statistical significance is evaluated by analysis of variance (ANOVA). †p-Values
of < 0.05 are considered statistically significant.
PMR: Percentage of methylated reference; TNM: Tumor, lymph nodes
and metastasis.
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alcohols and are associated with several human cancers,
including CRC [11]. Alcohol metabolism increases reactive
oxygen species (ROS) generation, resulting in oxidative
stress [12], and accumulation of ROS enhances arsenic-
induced tumor angiogenesis in CRC cells via the HIF-1α
pathway [13]. Alcohol promotes cancer progression by in-
ducing gene expression of epithelial-mesenchymal transi-
tion (EMT) genes, such as the transcription factor Snail,
by increasing epidermal growth factor receptor (EGFR)
transactivation and activating matrix metalloproteinases
(MMPs) [14].
Alcohol dehydrogenase, iron containing, 1 (ADHFE1)
located on chromosome 8q13.1 was cloned by Deng and
colleagues from a human fetal brain cDNA library [15].
ADHFE1 is related to members of the group III metal-
dependent alcohol dehydrogenase family [16], and en-
codes hydroxyacid-oxoacid transhydrogenase, which is
responsible for the oxidation of 4-hydroxybutyrate to
succinate semialdehyde [17]. The hypermethylation of
ADHFE1 was recently reported in CRC [18,19] and is
associated with differentiation [20]. However, the asso-
ciation between the hypermethylation of ADHFE1 and
alcohol in CRC has not been reported yet.
In this study, the hypermethylation of ADHFE1 was
identified in CRC using quantitative methylation-specific
polymerase chain reaction (QMSP). The expression level
of ADHFE1 in CRC tissues was compared to that in
adjacent normal tissues using real-time reverse transcriptase-
polymerase chain reaction (real-time PCR). We investi-
gated the demethylating effects of ADHFE1 using 5-aza-
2′-deoxycytidine. We analyzed the effect of alcohol on
methylation and expression of ADHFE1 as well as cell
proliferation in CRC cells.
Methods
Tissues
Fresh-frozen primary tumors (n = 73), paired tumors, and
adjacent normal tissues (n = 73) from CRC patients were
collected at the time of surgery at the Korea University
Medical Center. The clinicopathologic features of CRC
patients are summarized in Table 1. The “drinking group”
comprised individuals consuming more than 300 mL of al-
cohol three or more times per a week and the “non-drink-
ing” group contained individuals who did not consume
alcohol. The tissues were collected after obtaining informed
consent from the patients and the study was approved by
the Institutional Review Board of Korea University (IRB
No: KU-IRB-10-08-A-1). The diagnosis of CRC tissues was
acquired from pathology reports histological evaluations.
Cell lines
One normal colon cell line (CCD18Co) and 4 CRC cell
lines (HT-29; SW480, Dukes’ type B; DLD-1, Dukes’type C; LoVo, Dukes’ type C and stage IV) were ob-
tained from the American Type Culture Collection
(Manassas, VA, USA). CCD18Co cells were cultured in
Eagle’s minimum essential medium and the 4 CRC cells
were cultured in RPMI 1640 medium, all supplemented
with 10% fetal bovine serum (Hyclone, Logan, UT,
USA) and 1% penicillin/streptomycin (P/S; Life Tech-
nologies). The cells were maintained at 37°C and 5%
CO2 atmosphere.
Genomic DNA extraction
Genomic DNA was extracted using the QIAamp DNA
Mini Kit (Qiagen, Valencia, CA, USA) according to the
manufacturer’s recommendations. Tissue samples were
ground up by 3-mm diameter punches and then mixed
with 700 μL lysis buffer containing 20 μg/mL Labo Pass
protease K (Cosmo Gene Tech., Seoul, Korea), 20 mM
Tris∙HCl (pH 8.0), 5 mM EDTA (pH 8.0), 400 mM NaCl,
and 1% SDS solution (Sigma-Aldrich, St. Louis, MO,
USA). The mixed samples were incubated at 42°C over-
night. After incubation, genomic DNA was purified by
phenol/chloroform extraction, eluted in 100 μL of water,
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Fisher Scientific, Hudson, NH, USA).
Sodium bisulfite DNA modification
Two micrograms of genomic DNA in 20 μL of RNase-free
water was bisulfite converted using the EpiTect fast DNA
bisulfite kit (Qiagen) according to the manufacturer’s rec-
ommendations. The reaction was performed by mixing
85 μL of bisulfite mix solution and 35 μL of DNA protect
buffer in 200 μL PCR tubes at room temperature. The
bisulfite-converted genomic DNA was eluted from the
column with 100 μL of dH2O and stored at −80°C until
use.
Quantitative methylation specific PCR (QMSP)
Quantitative methylation status of the bisulfite-converted
genomic DNA was confirmed by quantitative real-time
PCR using the 7500 Real-Time PCR System (Applied
Biosystems, San Francisco, CA, USA) according to the
manufacturer’s recommendations. Methylation primers
were designed using the MethPrimer software (http://
www.urogene.org/methprimer/). MSP primer sequences
for the methylated sequence of ADHFE1 (−100 to +202,
position from translational start site +1): 5′- AGG GCG
GTA TTT AAA TTT TTC GAA TT -3′ (sense), 5′- CGC
GAA ACG AAT AAA CAA ACG CGA CCG A -3′ (anti-
sense) ); reference sequence of beta-actin (ACTB) (−1645
to −1513): 5′- TGG TGA TGG AGG AGG TTT AGT
AAG T −3′ (sense), 5′- AAC CAA TAA AAC CTA CTC
CTC CCT TAA −3′ (antisense). The product sizes were
303 bp and 132 bp respectively. PCR reactions were per-
formed using an optical 96-well tray in a final volume of
20 μL. The reaction mixture consisted of 5 μL of 2X Max-
ima SYBR Green/ROX qPCR master mix (Thermo Fisher
Scientific), 250 nM of each primer, and 100 ng of bisulfite-
converted DNA template. The QMSP program was as the
following: 95°C for 10 min, followed by 45 cycles at 95°C
for 15 s, and then 60°C for 1 min. After PCR, a thermal
melt profile was performed to examine the homogeneity
of the PCR application. Each DNA sample was analyzed
in triplicate, and the mean quantity was used for further
analysis. Relative quantification of the amplified gene
levels in the bisulfite-converted genomic DNA sample
was performed by measuring the threshold cycle (CT)
values of ADHFE1 and β-actin (ACTB). The mean quantity
of genes was divided by the mean quantity of ACTB and
was used for the normalization of input DNA. The
negative values for ACTB were excluded from the
methylation analysis. The bisulfite-converted genomic
DNA of a known concentration was prepared at 1, 1/4,
1/16, and 1/64 by serial dilutions, and used in a standard
curve for quantification. The modified genomic DNA
by CpG methyltransferase M.SssI (NEB, Ipswich, MA,
USA) was used as a positive control according to themanufacturer’s recommendations. DNA methylation ac-
cording to M.SssI was verified using the restriction
enzyme BstUI (NEB).mRNA extraction and cDNA synthesis
mRNA was extracted using an RNeasy Mini kit (Qiagen)
according to the manufacturer’s recommendations. mRNA
was eluted in 20 μL of diethyl pyrocarbonate (DEPC)
water (Qiagen) and quantified with a NanoDrop ND-100
device (Thermo Fisher Scientific). cDNA was synthesized
from 1 μg of mRNA from each sample using Moloney
murine leukemia virus reverse transcriptase (M-MLV RT)
and random hexamers (Promega, Madison, WI, USA).
The cDNA synthesis reaction was prepared according
to the manufacturer’s recommendations by mixing 1 μg
mRNA, 4 μL of 5× RT buffer, 1 μL of 500 nM oligo dT,
1 μL of a 10 mM dNTP solution, 0.5 μL of RNasin, 1 μL
of M-MLV RT, and 12.5 μL of distilled water in PCR
tubes. The mixture was incubated in 37°C for 1 h.
cDNA was diluted with 20 μL of distilled water and
stored at −80°C until use.Real-time PCR
mRNA expression was confirmed by quantitative real-
time PCR using a 7500 Real-Time PCR System (Applied
Biosystems) according to the manufacturer’s recommen-
dations. The primers were designed using Primer3 version
0.4.0 (http://primer3.ut.ee/). The specific primers were:
ADHFE1: 5′- TGC CAT TTT TGA CTA TGA ACA
CTT -3′(sense), 5′- GAC AGC CCT CTT CAG ATA
CTT AGC -3′(antisense); ACTB, 5′- AGA GCT ACG
AGC TGC CTG AC −3′ (sense) and 5′- AGC ACT
GTG TTG GCG TAC AG −3′ (antisense. The product
sizes of ADHFE1 and ACTB were 304 bp and 184 bp, re-
spectively. The PCR reaction was performed in a final
volume of 20 μL using an optical 96-well tray. The reac-
tion mixture consisted of 5 μL of 2× Maxima® SYBR
Green/ROX qPCR Master Mix (Thermo Fisher Scientific),
250 nM of each primer, and 100 ng of cDNA template.
The real-time PCR program was initiated at 95°C for
10 min, followed by 35 cycles of 95°C for 15 s and 60°C
for 1 min. The thermal melt profile was examined to as-
sess the homogeneity of the PCR application. Each DNA
sample was analyzed in triplicate, and the mean quantity
was used for further analysis. The relative levels of ampli-
fied mRNA in each sample were quantified by measuring
the threshold cycle (CT) values of target genes. The mean
quantity of each gene was divided by the mean quantity of
ACTB and was used for the normalization of input DNA.
cDNA of a known concentration was prepared at 1, 1/10,
1/100, and 1/1000 by serial dilutions and used as the
standard curve for quantification.
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To determine the optimal concentration of ethanol
(Sigma-Aldrich) in a normal colon cell line and 4 CRC
cell lines, we measured cell viability with the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay
(data not shown) according to the manufacturer’s recom-
mendations using MTT reagents (10 μL/well, 7.5 mg/mL
in phosphate-buffered saline, PBS) and dimethyl sulfoxide
(50 μL/well, Sigma-Aldrich). To identify the alteration of
methylation status by treatment with ethanol, cells were
seeded in 6-well culture plates (SPL LifeScience, Pocheon,
Korea) at a density of 0.5 × 105 cells per well. After 24 h,
the cells were treated with 100 mM ethanol for 72 h at
37°C in a 5% CO2 atmosphere. The cells were washed in
PBS three times and then harvested. The cells were
seeded at a density of 0.5 × 105 cells/well in a 6-well
plate, and after 24 h, the cells were treated with demeth-
ylation agent 30 μM 5-aza-2′-deoxycytidine (5-aza-dC)
for 72 h. The results were drawn from experiments
repeated at least three times.
ADHFE1 siRNA treatment
CCD18Co and DLD-1 cells were seeded at a density of
0.5 × 105 cells/well in a 6-well plate and allowed to grow
to 70% confluence for 24 h. Cells were serum-starved for
30 min before siRNA transfection. Transient transfections
were performed using a transfection reagent (Lipofec-
tamine 2000; Life Technologies, Carlsbad, CA, USA)
according to the manufacturer’s protocol. A commercial
ADHFE1 siRNA was purchased from Qiagen. The specific
primers were: ADHFE1 siRNA: 5′- GGA UGU UGA UGA
UGG CCU ATT -3′ (sense), 5′- UAG GCC AUC AUC
AAC AUC CAG -3′ (anti-sense); non-target siRNA: 5′-
UUC UCC GAA CGU GUC ACG UTT -3′ (sense), 5′-
ACG UGA CAC GUU CGG AGA ATT -3′ (anti-sense).
Fifty nM of siRNA and 6 μL of transfection reagent were
each diluted first with 100 μL of reduced serum media,
and then mixed. The mixtures were allowed to incubate
for 10 minutes at room temperature and then added drop-
wise to each culture well containing 1 mL of reduced
serum media. After 4 h, the medium was changed using
fresh complete medium. Cells were cultivated for 24 h,
48 h, or 72 h. The cells were washed in PBS (Sigma-
Aldrich) three times and then harvested.
Cell counting assay and cell image capture
After treatment with indicated agents, CCD18Co and
DLD-1 cells in 6-well plates were washed with PBS
(Sigma-Aldrich). The cells were detached with 0.05%
trypsin (Wellgene, Deagon, Korea) and 0.53 mM EDTA
(Wellgene, Deagon, Korea) for 2 min at 37°C. Eight
hundred microliters of media supplemented with 10%
FBS (Hyclone) was then added, and 20 μL of cells were
combined with 20 μL of 0.4% trypan blue solution(Sigma-Aldrich). The retained cells were transferred to
a counting chamber (Paul Marienfeld GmbH & Co. KG,
Lauda-Königshofen, Germany) and cells were counted
using Nikon TMS inverted stage microscope (Nikon
Instrument Inc., Melville, NY, USA). For counter stain-
ing, cells were fixed with 4% paraformaldehyde (Sigma-
Aldrich) for 15 min at room temperature, and the fixed
cells were washed three times in PBS (Sigma-Aldrich).
Cells were stained with Hoechst 33342 (Sigma-Aldrich)
for 10 min at room temperature without light and washed
with PBS (Sigma-Aldrich). Images of cells were obtained
using a LSM 700 Confocal Laser Scanning Microscope
(Carl Zeiss Co., Ltd., Jena, Germany). The results were
drawn from experiments repeated at least three times.Immunoblot analysis
Cells were grown in 6-well plates and treated with the
indicated agents. Following treatment, the media was as-
pirated and the cells were washed three times in ice-cold
PBS (Sigma-Aldrich) and lysed in 100 μL of lysis buffer.
The samples were then briefly sonicated, centrifuged for
5 min, and supernatants were boiled for 5 min at 95°C.
The supernatants were subjected to electrophoresis on so-
dium dodecyl sulfate polyacrylamide gel electrophoresis
(10%) gels, and transferred to polyvinylidene difluoride
membranes. The blots were incubated overnight at
room temperature with primary ADHFE1 antibody
(Sigma-Aldrich), and then washed six times in Tris-
buffered saline/0.1% Tween 20 prior to incubation with
horseradish peroxidase-conjugated secondary antibody
(anti-rabbit, Sigma-Aldrich) for 1 h at room temperature.
The blots were visualized using ECL (Amersham Bio-
sciences, Buckinghamshire, UK). Beta-actin (ACTB) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were
used as loading controls.Fluorescence-activated cell sorting (FACS) analysis
Cells treated with propidium iodide (PI) can be utilized
not only for assessment of the stages of the cell cycle
(G0/G1, S, G2/M), but also for identification of apop-
totic cells (hypodiploid, sub G0 peak). Half a million
cells were pelleted at 1000 × g for 5 min and were mixed
with 10 μl of Vindelov’s PI (Sigma-Aldrich) stain solu-
tion (1.21 g TRIS base, 584 mg NaCl, 10 mg RNAse,
50.1 mg PI, 1 ml Nonidet P40, pH 8.0) and 490 μl of
standard azide buffer(PBS buffer, 0.5% EDTA pH 8.0).
Cells were incubated at 4°C overnight and analyzed
using an FACS caliber flow cytometer (Becton-Dickin-
son, NJ, USA) at an excitation wavelength of 488 nm
and an emission wavelength of 525 nm. The 10,000 cells
were measured by gating the polymorphonuclear leuko-
cytes (PMN) population and analyzed using the BD
FACSDiva Software version 6. 1. 3 (Becton-Dickinson).
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MTT assay results were quantified using SoftMax® Pro
software (Molecular Devices, LLC). The methylated
intensity ratio of QMSP was determined as the per-
centage of methylated reference (PMR), and the PMR
value was defined as: [(ADHFE1)sample/(ACTB)sample]/
[( ADHFE1)M.SssI/(ACTB)M.SssI] × 100. A PMR value of
ten or more indicated hypermethylation. The signifi-
cance of the differences in PMR values was defined by
the chi-squared test, Fisher’s exact test, and ANOVA
using Sigma Stat (SPSS Inc., Chicago, IL, USA). In all
statistical tests, p-Values of < 0.05 were considered sta-
tistically significant. Real-time PCR and immunoblot
analysis data were compared and qualitative differ-
ences between samples were analyzed using Sigma Stat
(SPSS Inc.). p-Values of < 0.05 were considered statisti-
cally significant.
Results
ADHFE1 is hypermethylated and down regulated in CRC
To determine the methylation status of ADHFE1, we
analyzed the methylation status of 73 CRC tissues and























































Figure 1 The methylation status and mRNA expression levels of ADH
status of ADHFE1 in 73 CRC tissues and adjacent normal tissues is assessed us
significantly hypermethylated in drinking groups and non-drinking groups (C)
adjacent normal tissues was determined in 73 CRC tissues by real-time PCR. T
compared to adjacent normal tissues. D. The down regulation of ADHFE1 is p
< 0.05 were considered statistically significant. AdjN: Adjacent normal tissue; Thypermethylated in 69 out of 73 CRC tissues (95%) and
only 2 out of 73 adjacent normal tissues (3%). Compara-
tive analysis using percentage of methylated reference
(PMR) value also indicated that the methylation status
of ADHFE1 was much higher in CRC tissues compared
to adjacent normal tissues (Figure 1A). To verify whether
the mRNA expression of ADHFE1 is caused by aberrant
DNA methylation, we examined the expression level of
ADHFE1 in 73 CRC tissues and adjacent normal tissues
by real-time PCR. The mRNA expression of ADHFE1
was significantly reduced in CRC tissues compared to
adjacent normal tissues (Figure 1B). We performed
statistical analysis between the methylation of ADHFE1
and clinicopathologic features of CRC. The PMR value
of ADHFE1 was not significantly different in most clin-
icopathologic features except the alcohol consumption
in CRC tissues (Table 1). The methylation status of
ADHFE1 in CRC tissues was much higher in the non-
drinking group than the drinking group (p < 0.05,
Figure 1C). However, mRNA expression of ADHFE1
in CRC tissues, compared to adjacent normal tissues,
was more reduced in groups of drinking and old age






















































FE1 in CRC tissues and adjacent normal tissues. The methylation
ing QMSP. A, C. ADHFE1 is hypermethylated in CRC (A) and also
. B. The expression levels of ADHFE1 in 73 CRC tissues compared with
he mRNA expression of ADHFE1 is significantly decreased in CRC
resented in drinking groups and non-drinking groups. *,†p-Values of
: Colorectal cancer tissues; PMR,: Percentage of methylated reference.
Table 2 mRNA expression of ADHFE1 associated with CRC
risk factors
Characteristics mRNA expression of ADHFE1 p-value
AdjN T
Median (range) Median (range)
Colorectal cancer 1.98 (±0.21) 1.14 (±0.22) 0.007†
Age (years)
≤ 65 1.97 (±0.52) 1.54 (±0.41) 0.525
> 65 1.94 (±0.29) 1.04 (±0.30) 0.034†
Alcohol consumption
Non-drinking 1.96 (±0.29) 1.21 (±0.30) 0.078
Drinking 1.87 (±0.23) 0.94 (±0.23) 0.005†
Statistical significance is evaluated by analysis of variance (ANOVA). †p-Values
of < 0.05 are considered statistically significant.
AdjN: Adjacent normal tissue; T: Colorectal cancer tissues.
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The effect of methylation on mRNA expression was deter-
mined by MSP and real-time PCR analysis in 5-aza-dC
treated HT-29, SW-480, DLD-1, LoVo, and CCD18Co
cells. ADHFE1 was hypermethylated in 4 CRC cells and
demethylated by treatment with 5-aza-dC (Figure 2A).Figure 2 Changes of ADHFE1 methylation and expression by treatment
with 5-aza-dC in cells, the methylation status and expression levels of ADHFE1
A. ADHFE1 is hypermethylated in 4 CRC cells compared to normal colon cells
expression of ADHFE1 is reduced in 4 CRC cells but increased in all cells treate
5-aza-dC in CCD18Co. D. Protein expression of ADHFE1 is restored by 5-aza-dC
control. *p-Values of < 0.05 were considered statistically significant. +: Trea
methylated reference.The mRNA expression of ADHFE1 was relatively reduced
in 4 CRC cells compared with CCD18Co and was restored
by treatment with 5-aza-dC (Figure 2B). To confirm the
protein expression of ADHFE1, we measured ADHFE1
protein levels and estimated the change in protein expres-
sion by 5-aza-dC in all cell lines using western blot ana-
lysis. The basal protein level of ADHFE1 was lower in 4
CRC cells compare to that of CCD18Co cells, and protein
expression of ADHFE1 in 4 CRC cells increased upon
treatment with 5-aza-dC (Figure 2C). These results sug-
gest that promoter methylation of ADHFE1 regulates the
expression of ADHFE1.
Alcohol down-regulates the expression of ADHFE1 by
methylation in CRC cells
To examine the correlation between ADHFE1 methylation
and expression in the presence and absence of alcohol, the
methylation status and mRNA levels of ADHFE1 were
assessed by QMSP and real-time PCR analysis, respect-
ively, in 3 CRC cells after ethanol treatment. The methyla-
tion status of ADHFE1 was significantly induced in
SW480 and DLD-1 cell (Figure 3A), whereas its expres-
sion was decreased in HT-29, SW480, and DLD-1 cells bywith 5-aza-dC in CRC cells and normal colon cells. After treatment
are observed using QMSP, real-time PCR and immuno-blotting analysis.
and significantly demethylated in 4 CRC cells by 5-aza-dC. B. The mRNA
d with 5-aza-dC. C. The protein expression of ADHFE1 is not affected by
in 4 CRC cells. Expression of ACTB and GAPDH is used as a loading
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Figure 3 Changes in methylation and expression of ADHFE1 by ethanol treatment. The methylation and expression changes of ADHFE1 are
determined in HT-29, SW480, and DLD-1 cells by treatments with ethanol using QMSP, real-time PCR and immunoblot analysis. A. The methylation
status of ADHFE1 is significantly increased by ethanol treatment in 2 CRC cells. B. ADHFE1 expression is diminished by ethanol in 3 CRC cells. C. After
treatment with ethanol in CRC cells, the protein expression of ADHFE1 is decreased in a concentration-dependent manner. Expression of GAPDH is used
as a loading control. *p-Values of < 0.05 were considered statistically significant; PMR: Percentage of methylated reference.
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In addition, we investigated the protein levels of
ADHFE1 in 3 CRC cells after treatment with various
concentrations of ethanol for 3 days. After treatment
with ethanol, the protein expression of ADHFE1 was de-
creased in a concentration-dependent manner in both
cells (Figure 3C). These results suggest that alcohol pro-
motes the hypermethylation of ADHFE1 and methylation-
mediated silencing of ADHFE1.
Alcohol induces the proliferation of CRC cells and
down-expression of ADHFE1
To investigate the function of ADHFE1, its expression
was inhibited by treatment with ethanol and transfection
of ADHFE1 siRNA in HT-29, SW480, and DLD-1 cells.
Cell viability and cell proliferation were then analyzed
using MTT and a cell counting assay. The cell viability
of HT-29, SW480, and DLD-1 cells was significantly
increased by treatment with a combination of ethanol
and ADHFE1 siRNA. HT-29 cells was increased the cell
viability by ethanol as much as co-treatment (Figure 4A).The cell counting assay showed that proliferation of 3
CRC cells was increased by ethanol and siRNA. Growth of
DLD-1 cells by co-treatment was significantly higher than
each treatment with alcohol and siRNA (Figure 4B). To
confirm the effect of ADHFE1 down regulation on cell
proliferation, cells were stained with Hoechst 33342 after
ethanol treatment and siRNA transfection. The number
of HT-29, SW480, and DLD-1 cells was increased by
ethanol, siRNA, and co-treatment (Figure 4C). Further-
more, mRNA and protein expression of ADHFE1 were
significantly decreased in 3 CRC cells by treatment with
alcohol, siRNA, and co-treatment (Figure 4D, 4E). These
results suggest that methylation-mediated down regula-
tion of ADHFE1 by alcohol may be associated with cell
proliferation of CRC cells.
Discussion
Recently, aberrant methylation of ADHFE1 promoter
was identified by a genome-wide methylation profiling
screen using an array-based chip assay [18,19], and
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Figure 4 (See legend on next page.)
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Figure 4 The effect of ADHFE1 down regulation on cell viability and proliferation. The cell viability and proliferation of HT-29, SW480, and
DLD-1 cells after ethanol treatment, transfection of ADHFE1 siRNA and combined treatment are determined by MTT, cell counting, and counter
staining assay. A. Cell viability of 3 CRC cells is significantly increased by treatment with ethanol, siRNA, and combination of both. B. Cell proliferation of
3 CRC cells is significantly increased by ethanol, siRNA, and co-treatment. C. The captured images of cells using Hoechst 33342 show that the number
of 3 CRC cells is increased by ethanol, siRNA, and co-treatment. D. The mRNA expression of ADHFE1 is significantly decreased in 3 CRC cells by
treatment with ethanol, siRNA, and combination of both. E. ADHFE1 protein expression is decreased in 3 CRC cells by treatment with ethanol,
siRNA, and combination of both. GAPDH was used as a loading control. *p-Values of < 0.05 were considered statistically significant. +: Treated
with agent; −: Non-treated with agent.
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hypermethylation of ADHFE1 in CRC tissues compared
to adjacent normal tissues using QMSP analysis. The
PMR value of methylation status by QMSP was dichoto-
mized at 4 PMR or 10 PMR for statistical purposes, as de-
scribed previously [21,22]. In our experiments, 10 PMR or
higher was considered as a cutoff to indicate a methylated
state, whereas less than 10 PMR was considered as a cutoff
to indicate an unmethylated state. Interestingly, the
methylation status of ADHFE1 in CRC tissues was higher
in the non-drinking group than in the drinking group, but
the expression of ADHFE1 in CRC tissues compared to
adjacent normal tissues was lower in the drinking group
(Figure 1). The inverse correlation between ADHFE1
methylation and expression was highly significant in
the drinking group. Based on this result, promoter
methylation of ADHFE1 may be the main factor affect-
ing its expression in the drinking group.
The age-associated hypermethylation and methylation-
mediated silencing of several genes was reported in hu-
man prostate [23], colon tissues [24] and peripheral blood
[25]. Based on the results presented here, we found no
age-dependent ADHFE1 methylation but we identified
that ADHFE1 down regulation in CRC tissues compared
to adjacent normal tissues was more significant in the old
age group than the young age group. The inverse correl-
ation between methylation and expression of ADHFE1 in
9 out of 12 CRC cell lines by 5-aza-dC was reported by
Tae C.H. et al. [20]. In this study, we obtained the same re-
sults in 4 CRC cell lines (Figure 2). This result suggests
that the promoter methylation of ADHFE1 may be the key
regulator of ADHFE1 expression in CRC cells.
Alcohol is a major risk factor well known for the pro-
gression of CRC [10,26] and alters the methylation status
of genes. Hypermethylation of alpha synuclein was sig-
nificantly presented in peripheral blood of patients with
chronic alcoholism [27]. Recently, array-based study has
reported that various genes were hypermethylated in
peripheral blood of patients with alcohol dependency
compared to healthy controls [28]. We found that alcohol
induced the hypermethylation of ADHFE1 and decreased
its expression in CRC cells as well as normal colon cells.
Down regulation of ADHFE1 by siRNA affected cellgrowth in CRC cells. The survival rate and cell growth of
SW480 and DLD-1 cells were significantly increased by
treatment with a combination of ethanol and ADHFE1
siRNA than each individual treatment (Figure 4). The re-
sult demonstrates a synergetic effect between ethanol and
ADHFE1 siRNA. The viability of HT-29 cells was affected
more by the treatment with ethanol than down expression
of ADHFE. In addition, we confirmed the viability of CRC
cells after co-treatment with 5-aza-dC and ethanol. The
viability of CRC cells was significantly decreased after
treatment with 5-aza-dC. On the other hand, co-treated
cells had smaller range of decline compared with 5-aza-
dC treated cells in HT-29 and SW480. The viability of
DLD-1 cells were not affected by co-treatment (Additional
file 1: Figure S1). In contrast, the down regulation of
ADHFE1 by ethanol and siRNA had opposite effects on
the viability and proliferation of CCD18Co, normal colon
fibroblast cells (Additional file 2: Figure S2). CCD18Co
was increased rate of apoptosis by treatment with ethanol,
siRNA, and combination of both, but DLD-1 was not af-
fected (Additional file 3: Figure S3). Previous studies
have found that several genes, including interleukin 6
and tumor necrosis factor-alpha, have opposite func-
tions in normal and tumor cells [29,30]. Taken together,
our results provide evidence for different functions of
ADHFE1 in normal colon cells and CRC cells.Conclusions
We found that ADHFE1 was hypermethylated in CRC
tissues compared to adjacent normal tissues and that the
expression of ADHFE1 was significantly reduced in the
alcohol drinking and old age group. In addition, alcohol
induced the hypermethylation of ADHFE1 and decreased
its expression in HT-29, SW480, and DLD-1 cells. The
down regulation of ADHFE1 by alcohol and ADHFE1 siRNA
induced the growth of 3 CRC cells, and co-treatment
with alcohol and siRNA greatly increased cell prolifera-
tion in SW480 and DLD-1 cells. These results suggest
that hypermethylation of the ADHFE1 promoter by al-
cohol leads to a decrease in ADHFE1 expression and
methylation-mediated silencing of ADHFE1 may be in-
duced the progression of CRC cells.
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Additional file 1: Figure S1. The effect of ethanol, 5-aza-dC and
co-treatment on the viability of CRC cells. The viability of HT-29, SW480,
and DLD-1 cells after treatment ethanol, 5-aza-dC, and combination of
both is determined by MTT assay. The viability of HT-29, SW480, and
DLD-1 cells is reduced by treatment with 5-aza-dC. However, viability of
HT-29 and SW480 cells treated with both 5-aza-dC and ethanol has
smaller range of decline, compared to those treated with 5-aza-dC. The
viability of DLD-1 cells is not affected by co-treatment with 5-aza-dC and
ethanol. *Indicates the increase in cell viability by treatment with agent.
†Indicates the decrease in cell viability by treatment with agent.
Additional file 2: Figure S2. The effect of ADHFE1 down regulation on
cell viability and proliferation in normal colon cells. The cell viability and
proliferation of CCD18Co after ethanol treatment, transfection of ADHFE1
siRNA, and combined treatment are determined by MTT, cell counting,
and counter staining assay. A. The viability of CCD18Co cells is significantly
decreased by ethanol, siRNA, and co-treatment. B. The proliferation of
CCD18Co cells is significantly decreased by ethanol, siRNA, and co-
treatment. C. The captured images of CCD18Co using Hoechst 33342 show
that the number of CCD18Co cells is decreased by ethanol, siRNA, and
co-treatment. D. ADHFE1 protein expression is decreased in CCD18Co cells
treated with ethanol, siRNA, and combination of both. GAPDH was used as a
loading control. *p-Values of < 0.05 were considered as statistically
significant. +: Treated with agent; −: Treated without agent.
Additional file 3: Figure S3. The effect of ADHFE1 down regulation on
apoptosis in CCD18Co and DLD-1 cells. Apoptosis of CCD18Co and DLD-1
after ethanol treatment, transfection of ADHFE1 siRNA, and combined
treatment is determined by FACS analysis. Apotosis of CCD18Co cells is
induced by ethanol, ADHFE1 siRNA, and co-treatment, but that of DLD-1
cell are not affected.
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